Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly

Pituitary

Volumn 3, Issue 3, 2000, Pages 193-197

  Lorcy, Yannick ^a   Dejager, Sylvie ^b   Chanson, Philippe ^c  

^a SERVICE DE RHUMATOLOGIE   (France)

^b NOVARTIS PHARMA K K   (Japan)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Acromegaly; GH; IGF 1; Octreotide; Pituitary; Somatostatin analog

Indexed keywords

GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INJECTION; MALE; PARAMETER; PRIORITY JOURNAL;

ACROMEGALY; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034433231     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011416112730     Document Type: Article

References (27)

1. Octreotide
2. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumors
3. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)
4. Sandostatin LAR in acromegalic patients: A dose-range study
5. [Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly]
6. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
7. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships
8. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients
9. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
10. Results of an European multicenter study with Sandostatin LAR in acromegalic patients
11. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR)
12. Surgical management of acromegaly
13. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience
14. Radiation therapy of acromegaly
15. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
16. Medical therapy for acromegaly
17. Pituitary tumors: Overview of therapeutic options
18. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients
19. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide
20. A comparison of lanreotide and octreotide LAR for treatment of acromegaly
21. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide
22. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
23. Clinical results of long-term slow-release lanreotide treatment of acromegaly
24. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
25. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormones secretion
26. Sandostatin LAR in acromegalic patients: Long-term treatment
27. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: Clinical implications